$4.34
1.59% yesterday
Nasdaq, Nov 13, 10:00 pm CET
ISIN
US9216591084
Symbol
VNDA

Vanda Pharmaceuticals Inc. Stock price

$4.34
-0.89 17.02% 1M
+0.36 9.05% 6M
-0.45 9.39% YTD
-1.12 20.51% 1Y
-6.20 58.82% 3Y
-8.83 67.05% 5Y
-5.23 54.65% 10Y
-5.34 55.17% 20Y
Nasdaq, Closing price Thu, Nov 13 2025
-0.07 1.59%
ISIN
US9216591084
Symbol
VNDA
Industry

Key metrics

Basic
Market capitalization
$260.6m
Enterprise Value
$-28.0m
Net debt
positive
Cash
$293.8m
Shares outstanding
59.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.1
EV/Sales
negative | negative
EV/FCF
0.3
P/B
0.6
Financial Health
Equity Ratio
82.1%
Return on Equity
-3.5%
ROCE
-25.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$212.1m | $227.2m
EBITDA
$-114.1m | $-38.0m
EBIT
$-121.1m | $-140.6m
Net Income
$-84.2m | $-108.1m
Free Cash Flow
$-83.0m
Growth (TTM | estimate)
Revenue
11.1% | 14.3%
EBITDA
-268.0% | -13.9%
EBIT
-223.1% | -245.9%
Net Income
-413.7% | -472.0%
Free Cash Flow
-355.8%
Margin (TTM | estimate)
Gross
94.4%
EBITDA
-53.8% | -16.7%
EBIT
-57.1%
Net
-39.7% | -47.6%
Free Cash Flow
-39.1%
More
EPS
$-1.4
FCF per Share
$-1.4
Short interest
7.0%
Employees
368
Rev per Employee
$540.0k
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
78%
Hold
22%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
212 212
11% 11%
100%
- Direct Costs 12 12
3% 3%
6%
200 200
12% 12%
94%
- Selling and Administrative Expenses 214 214
64% 64%
101%
- Research and Development Expense 100 100
27% 27%
47%
-114 -114
268% 268%
-54%
- Depreciation and Amortization 7.01 7.01
8% 8%
3%
EBIT (Operating Income) EBIT -121 -121
223% 223%
-57%
Net Profit -84 -84
414% 414%
-40%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
8 days ago
WASHINGTON , Nov. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 Healthcare Conference in New York City on Wednesday, November 12, 2025. A corporate presentation is scheduled for 4:40 p.m.
Neutral
Seeking Alpha
15 days ago
Vanda Pharmaceuticals Inc. ( VNDA ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Kevin Moran - Senior VP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman of The Board Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator ...
Neutral
PRNewsWire
15 days ago
Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024 BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026 Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date of December 30, 2025 Imsidolimab BLA in generalized pustular psoriasis expected t...
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 368
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today